PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

EQRx announces further results from phase 3 trial of sugemalimab

The study involved patients with locally advanced, unresectable stage 3 non-small cell lung cancer.

EQRx has announced a late-breaking oral presentation of updated data from its phase 3 GEMSTONE-301 trial of sugemalimab in non-small cell lung cancer (NSCLC).

In the updated results from the study, which follow the original data cut off from March 2022, sugemalimab demonstrated a sustained progression-free survival benefit. This emerging data – which was presented at the International Association for the Study of Lung Cancer (IASLC) 2022 World Conference on Lung Cancer – further demonstrates its potential as consolidation therapy for people with locally advanced, unresectable stage 3 non-small cell lung cancer.

As of the March 2022 data cut-off, the final progression-free survival analysis had shown that sugemalimab continued to demonstrate improvement in PFS compared to placebo as consolidation therapy for patients with locally advanced, unresectable stage 3 NSCLC without disease progression after concurrent or sequential chemoradiotherapy.

Vince Miller, physician-in-chief at EQRx, explained: “The inclusion of patients who had received sequential chemoradiotherapy in this trial is of particular importance as patients often cannot tolerate concurrent chemoradiotherapy or cannot access it due to a variety of factors.”

“There is currently no immune checkpoint inhibitor approved as a consolidation option for these patients, estimated to represent as many as 25% of people with unresectable stage 3 non-small cell lung cancer in the US,” he added.

The safety profile for sugemalimab was consistent with previously reported results, and no new safety signals were identified within the follow-up period.

Lung cancer is the leading cause of cancer death for men and women worldwide. Furthermore, non-small cell lung cancer is the most common type of lung cancer, accounting for 85% of all lung cancer diagnoses.

The main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma and large cell carcinoma, while treatment options include surgery, radiation therapy, chemotherapy, targeted therapy and immunotherapy.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026